Toxicology: Open Access
Open Access

Renal Cell Carcinoma the most common form of kidney cancer poses significant challenges in treatment due to its aggressive nature and potential for metastasis. Historically, radical nephrectomy, the complete removal of the affected kidney, has been the standard treatment for localized RCC. However, advancements in medical science and surgical techniques have led to the emergence of renal preservation therapy as a groundbreaking approach that aims to preserve kidney function while effectively treating the cancer. In this article, we delve into the concept of renal preservation therapy and its impact on patients with RCC.

Age and Charlson score impacted overall survival on the study with multivariate analysis, and cardiovascular events were usually a leading cause of mortality, driven by chronic renal failure. It should be considered if the patient will have the probability to die of the other unrelated disease. Baseline clinical characteristics of SRMs do not allow to reliably predicting the clinical outcome but available AS studies showed the chance of progression and metastasis is low in these selected cases. No clinically relevant tumor marker could help the AS now. Patients should know the following issues: SRMs are most malignant and RCC is life threatening. The aggressiveness cannot be precisely predicted. Growth rate does not predict malignancy and some SRM will show fast growth and aggressive behavior during surveillance. They also should know possible window of opportunity for NSS may be lost, and loss the opportunity of cure if metastases occur [1].

In the current studies, cry ablation may have similar efficacy and complication rate as RFA. The surgical approach allows placement of cry therapy probes into the lesions under direct vision. Realtime visual and continuous ultra sonographic monitoring provides precise control of the ice ball formation and extension. LCA is better to approach anterior and medical lesions to avoid of nearby tissue injury, but patients still need to receive general anesthesia and inherent risks of surgical exploration and dissection. Percutaneous CA is ideal for posterior lesion and usually could be performed under sedation/local anaesthesia. Comparing with PN, LCA results in higher risk of local tumor progression but a lower risk of perioperative complication. No significant differences in efficacy were found between these two ablative techniques [2].

Understanding renal preservation therapy

Renal preservation therapy, also known as nephron-sparing surgery or partial nephrectomy, involves the surgical removal of the tumor while preserving the unaffected, healthy portion of the kidney. This innovative approach seeks to maintain renal function and minimize the risk of chronic kidney disease and associated complications after treatment. Renal preservation therapy is particularly suitable for patients with small renal masses, tumors in a solitary kidney, or bilateral RCC, where preserving kidney function is crucial [3].

Advantages of renal preservation therapy

Kidney function preservation: By conserving the unaffected portion of the kidney, renal preservation therapy significantly reduces the risk of CKD, end-stage renal disease, and the need for dialysis or kidney transplantation. Preserving renal function is vital for maintaining overall health and quality of life. Minimizing Surgical Complications: Compared to radical nephrectomy, partial nephrectomy has a lower risk of postoperative complications such as infection, bleeding, and urinary leaks. The preservation of the kidney's anatomical and physiological integrity supports quicker recovery and shorter hospital stays.

Enhanced oncological outcomes: Renal preservation therapy achieves comparable cancer control outcomes to radical nephrectomy in selected cases. Studies have shown that properly performed partial nephrectomy offers excellent cancer-specific survival rates, making it a reliable treatment option for localized RCC [4].

Future treatment options: By preserving renal function, patients who may require additional therapies, such as immunotherapies or targeted therapies, have a broader range of treatment options available. This flexibility is particularly valuable in cases of disease recurrence or metastasis.

Surgical techniques and advancements

Renal preservation therapy can be performed through different surgical approaches, including open surgery, laparoscopic surgery, and robot-assisted laparoscopic surgery. The choice of technique depends on the surgeon's expertise and the patient's specific needs. Additionally, advancements in imaging technology, such as intraoperative ultrasound and image-guided navigation systems, have improved surgical precision and enhanced the success rates of partial nephrectomy [5].

Patient selection and considerations

Patient selection plays a vital role in determining the appropriateness of renal preservation therapy. Factors such as tumor size, location, and histological characteristics are considered to ensure optimal outcomes. Close collaboration between urologists, radiologists, and oncologists is essential in assessing the suitability of patients for partial nephrectomy and determining the best treatment strategy for each individual [6].

Discussion

Renal preservation therapy, also known as nephron-sparing surgery or partial nephrectomy, is a revolutionary approach to the treatment of Renal Cell Carcinoma. Traditionally, RCC treatment involved radical nephrectomy, which entailed removing the entire affected kidney. However, renal preservation therapy has emerged as a groundbreaking alternative that aims to preserve kidney function while effectively treating the cancer.

One of the key advantages of renal preservation therapy is the preservation of kidney function. By removing only the tumor and sparing the unaffected, healthy portion of the kidney, this approach significantly reduces the risk of chronic kidney disease and its associated complications. Preserving kidney function is crucial for maintaining overall health and quality of life in RCC patients [7].

In addition to preserving kidney function, renal preservation therapy offers several other benefits. It minimizes surgical complications compared to radical nephrectomy. The preservation of the kidney's anatomical and physiological integrity supports quicker recovery and shorter hospital stays. Patients undergoing renal preservation therapy often experience improved postoperative outcomes and reduced risks of infection, bleeding, and urinary leaks.

Furthermore, renal preservation therapy has demonstrated comparable cancer control outcomes to radical nephrectomy in selected cases. Properly performed partial nephrectomy offers excellent cancer-specific survival rates, making it a reliable treatment option for localized RCC. The approach is particularly suitable for patients with small renal masses, tumors in a solitary kidney, or bilateral RCC, where preserving kidney function is of utmost importance [8].

Advancements in surgical techniques and imaging technology have further enhanced the success rates of renal preservation therapy. Surgeons can utilize open surgery, laparoscopic surgery, or robotassisted laparoscopic surgery based on their expertise and the patient's specific needs. Intraoperative ultrasound and image-guided navigation systems assist in precise tumor localization and removal, optimizing the surgical outcome.

However, patient selection is critical for the success of renal preservation therapy. Factors such as tumor size, location, and histological characteristics are carefully evaluated to ensure optimal outcomes. A multidisciplinary approach involving urologists, radiologists, and oncologists is crucial in assessing patient suitability for partial nephrectomy and determining the best treatment strategy for each individual [9].

Renal preservation therapy not only addresses the immediate treatment needs of RCC but also offers long-term benefits. By preserving renal function, patients have a broader range of treatment options available for potential future therapies such as immunotherapies or targeted therapies. This flexibility is particularly valuable in cases of disease recurrence or metastasis.

In conclusion, renal preservation therapy represents a revolutionary approach in the management of RCC. By striking a balance between cancer control and kidney function preservation, this innovative treatment modality offers improved quality of life, reduced long-term complications, and expanded treatment options for patients. With ongoing advancements in medical research and surgical techniques, renal preservation therapy continues to evolve, bringing new hope to individuals diagnosed with RCC [10].

Conclusion

Renal preservation therapy, in the form of partial nephrectomy, represents a significant advancement in the treatment of renal cell carcinoma. By striking a balance between cancer control and kidney function preservation, this approach offers improved quality of life and reduced long-term complications for patients. Surgery is still the gold standard in the management of SRMs. Nephron sparing surgery partial nephrectomy is the best option whenever it could be used. RFA/CA are reasonable options for those old and high-risk patients that till wish active treatment for SRMs. New modality like HIFU is still under evaluation. Active surveillance should be restricted to the patients with high-surgical risk, elderly, infirm or who refuses surgery. For NSS/PN, evolution is from open partial nephrectomy to minimal invasive treatment. It is reasonable to choose the best therapeutic method among varieties of treatment modalities according to patients’ age, physical status, and financial aid to maximize the treatment effect among cancer control, patient morbidity, and preservation of renal function. As medical research and surgical techniques continue to evolve, renal preservation therapy is likely to become even more refined, enabling more individuals to benefit from this revolutionary approach to treating RCC.

Conflict of Interest

None

Acknowledgement

None

1. Metallo CM, Heiden MG (2013) Understanding metabolic regulation and its influence on cell physiology. Mol Cell 49: 388-398.

Google Scholar, Crossref, Indexed at

2. Madu CO, Lu Y (2010) Novel diagnostic biomarkers for prostate cancer. Int J Cancer 1: 150-177.

Google Scholar, Crossref, Indexed at

3. Hernandez LM, Blazer DG, Genes DG (2006) Behavior and the Social Environment Moving beyond the Nature/Nurture Debate, the National Academies Press. Nurture Debate 13: 23-30.

Google Scholar, Crossref, Indexed at

4. Fahy E, Subramaniam S, Brown HA (200) A comprehensive classification system for lipids. J Lipids 46: 839-861.

Google Scholar, Crossref, Indexed at

5. Wickramasinghe S, Medrano JF (2011) Primer on genes encoding enzymes in silica acid metabolism in mammals. Biochimie 93: 1641-1646.

Google Scholar, Crossref, Indexed at

6. Miyagi T, Yamaguchi K (2007) Silica acids in Comprehensive Glycoscience. Angew Chem Int Ed Engl 3: 297-322.

Google Scholar, Crossref, Indexed at

7. Berardinelli W (1954) An undiagnosed endocrinometabolic syndrome. J Clin Endocr 14: 193-204.

Google Scholar, Crossref, Indexed at

8. Seip M, Trygstad O (1963) Generalized lip dystrophy. Ital J Pediatr 38: 447-453.

Google Scholar, Crossref, Indexed at

9. Windpassinger C, Auer-Grumbach M, Irobi J (2004) Heterozygous missense mutations in BSCL2 is associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 36: 271-276.

Google Scholar, Crossref, Indexed at

10. Garfield AS, Chan WS, Dennis RJ, Ito D, Heisler LK, et al. (2012) Neuroanatomical characterization of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain. PLoS One 7: 9.

Google Scholar, Crossref, Indexed at